ELEKTA TO DELIVER LEKSELL GAMMA KNIFE® TO ST. PETERSBURG, RUSSIA


ELEKTA TO DELIVER LEKSELL GAMMA KNIFE® TO ST. PETERSBURG, RUSSIA

PRESS RELEASE
Stockholm, Sweden, August 10, 2007

Elekta today announced an order to deliver a Leksell Gamma Knife® 4C, to a new
hospital under construction in St. Petersburg, Russia, that will become the
second hospital in Russia to offer non-invasive radiosurgery for tumors and
other brain disorders.

Elekta today announced an order to deliver a Leksell Gamma Knife® 4C, to a new
hospital under construction in St. Petersburg, Russia, that will become the
second hospital in Russia to offer non-invasive radiosurgery for tumors and
other brain disorders. 

The Diagnostic and Treatment Center at the International Institute of Biological
Systems in St. Petersburg, Russia, will open up for patients in the spring of
2008 as privately owned center of excellence for the treatment of neurological
disorders. 

Following the installation of Leksell Gamma Knife, physicians at the center will
be able to offer state-of-the-art technology for non-invasive brain surgery to
patients in Russia and from neighboring countries. 

“There are large groups of patients in Russia with brain tumors, arteriovenous
malformations and other brain disorders that will benefit from our purchase of
Leksell Gamma Knife, patients that otherwise had to rely on more unproven and
less precise technologies for radiosurgery”, comments Dr. Arkadi Stolpner,
President of the Diagnostic and Treatment Center at the International Institute
of Biological Systems. “With this installation we will take a huge step in
increasing the treatment capacity in Russia. Stereotactic radiosurgery with
Leksell Gamma Knife is an efficient and well-proven method and there is a great
need for this unique technology”, continues Dr. Stolpner.

Pioneered by Elekta, stereotactic radiosurgery involves delivering a single,
high dose of radiation to a small and critically located target in the brain.
Gamma Knife surgery has replaced the scalpel in intracranial neurosurgery. And,
by doing so, it has dramatically widened treatment possibilities for physicians
and patients. 

Gamma Knife surgery provides pinpoint accuracy, unmatched efficiency and
outstanding results. Patients benefit from fast, painless treatment, often
conducted in an outpatient surgical setting without the need for general
anesthesia or even convalescence. To date, about 500,000 patients have undergone
Gamma Knife surgery.  

Today, Gamma Knife surgery is performed in hundreds of leading hospitals and
clinics around the world. Around 50,000 patients undergo Gamma Knife surgery
every year, and this unique procedure has an impressive scientific track record
with more than 70,000 patients documented in peer-reviewed articles. No other
method in this field has gained greater clinical acceptance.

********

For further information, please contact:

Peter Ejemyr
Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile)
e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

Attachments

08092244.pdf